Lv5
954 积分 2025-08-27 加入
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
9天前
已完结
Precision Immunotherapy to Improve Sepsis Outcomes
1个月前
已完结
Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit?
1个月前
已完结
Biomarkers in Pediatric Sepsis: A Review of Recent Literature
2个月前
已关闭
Effects of a cytokine inhibitor, JTE-607, on the response to endotoxin in healthy human volunteers
2个月前
已关闭
Studying the therapeutic potential and N-glycosylation of interleukin 13 receptor alpha 2
2个月前
已关闭
The Proinflammatory Cytokines Interleukin-l and Tumor Necrosis Factor and Treatment of the Septic Shock Syndrome
2个月前
已完结
IL-1 Family Blockade in Cytokine Storm Syndromes
2个月前
已完结
IL-6 Blockade in Cytokine Storm Syndromes
2个月前
已完结
Changing epidemiology, global trends and implications for outcomes of NAFLD
2个月前
已完结
皖公网安备34019202002308
